Head Regulatory Affairs, Bayer AG
After studying pharmacy at the University of Bonn, Max Wegner commenced his PhD in pharmacology at Bayer and started in Regulatory Affairs as a Dossier Manager in 1996 in Wuppertal. Since then, Max has been employed in various functions within Product Development at Bayer and also...
Read More →JM
Vice President, Scientific Advocacy, Pharmaceutical Research and Manufacturers of America (PhRMA)
Jim Mayne is Vice President, Science & Regulatory Advocacy at PhRMA, where he provides leadership for PhRMA involvement in a number of science based public-private partnerships and works to support pharma industry efforts to evolve the contemporary R&D ecosystem and drug development...
Read More →
President and Chief Executive Officer, Alliance for Aging Research
Susan Peschin, MHS, is president and CEO at the Alliance for Aging Research the leading national non-profit organization dedicated to accelerating research to improve aging and health. Ms. Peschin has led the Alliance in efforts to: boost older adult immunization rates; increase NIH...
Read More →
Director, Office of New Drugs, CDER, FDA
Peter Stein, M.D., is the Director of CDER’s Office of New Drugs (OND). OND is responsible for the regulatory oversight of investigational studies during drug development and decisions regarding marketing approval for new (innovator or non-generic) drugs, including decisions related...
Read More →